{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 58/80', '7.3.6. Analyses of Safety Data', 'All safety analyses will be performed using the Safety Analysis Set (Section 7.2.6). All safety', 'data collected on or after the first dose of IMP administration up to the last contact after the last', 'dose of IMP, unless specified otherwise, will be summarized by treatment group according to', 'the IMP received. Clinical safety will be addressed by assessing AEs, laboratory assessments,', 'physical examinations, vital signs, and 12-lead ECGs.', '7.3.6.1.', 'Extent of Exposure', \"A subject's extent of exposure to IMP will be generated from the IMP administration page of\", 'the CRF. Exposure data will be summarized by treatment group. Duration of exposure to IMP', 'will be expressed as the number of days between the first and last dose of IMP, inclusive,', 'regardless of temporary interruptions in IMP administration and summarized by treatment', 'group.', '7.3.6.2.', 'Adverse Events', 'Clinical and laboratory AEs will be coded using the latest version of the Medical Dictionary', 'for Regulatory Activities. System Organ Class (SOC), High Level Group Term, High-Level', 'Term, Preferred Term, and Lower-Level Term will be attached to the clinical database.', 'The following AEs will be considered as treatment-emergent AEs (TEAEs):', 'Any AE with an onset date on or after the start of IMP intake and no later than 30 days after', 'last dose of IMP, or any worsening of any AE on or after the start of IMP intake.', 'AEs reported before the start of IMP or later than 30 days after the last dose of IMP will be', 'listed.', 'In addition, summaries and/or listings will be provided for the suspected symptoms/AEs of flare', 'with an onset date on or after the IMP start date until the EoS (including information from', 'Follow-up Visit 2).', 'Summaries (number and percentage of subjects) of TEAEs per subject by SOC and Preferred', 'Term will be provided by treatment group. TEAEs will also be summarized by causal', 'relationship to IMP and severity. In addition, TEAEs leading to premature discontinuation of', 'IMP will be summarized and listed. Also, all SAEs, including the non-treatment-emergent', 'SAEs, will be listed.', '7.3.6.3.', 'Clinical Laboratory Evaluations', 'Laboratory assessments will be analyzed descriptively. Changes from baseline (Day 1 before', 'IMP intake) and shifts according to normal ranges will be presented as well. Analyses will be', 'done per treatment group.', '7.3.6.4.', 'Physical Examinations', 'Only abnormal post-baseline physical examination results will be listed.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 59/80', '7.3.6.5.', 'Vital Signs', 'Vital signs will be analyzed descriptively. Changes from baseline and shifts according to normal', 'ranges will be presented as well. Analyses will be done per treatment group.', '7.3.6.6.', '12-Lead Electrocardiogram', 'A descriptive analysis will be done for the 12-lead ECG. Changes from baseline and shifts', 'according to normal ranges will be presented as well. Analyses will be done per treatment', 'group.', '7.3.9. Analysis of Other Assessments', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 60/80', '8.', 'DATA MONITORING', '8.1.', 'MEDICAL REVIEW', 'An independent medical safety review will be implemented for this clinical study. The review', 'will be conducted by an independent blinded clinician experienced in the field of systemic', 'sclerosis. The independent expert will review safety data and assess any potential safety issues', 'arising during the conduct of the clinical study. This process will be described in a separate', '\"Independent Medical Safety Review Charter\\'.', '9.', 'SAFETY REPORTING', '9.1.', 'DEFINITIONS OF ADVERSE EVENTS, SERIOUS ADVERSE', 'EVENTS, AND SPECIAL SITUATIONS', '9.1.1. Adverse Events', 'An AE is any untoward medical occurrence, new or worsening of any pre-existing condition,', 'in a clinical study subject administered a medicinal product and which does not necessarily', 'have to have a causal relationship with this treatment.', 'An AE can therefore be any unfavorable and unintended sign (e.g. an abnormal laboratory', 'finding), symptom, or disease temporally associated with the use of a medicinal product,', 'whether or not considered related. AEs may also include pre- or post-treatment complications', 'that occur as a result of CSP-specified procedures, worsening of the targeted disease, overdose,', 'drug abuse/misuse reports, or occupational exposure. Pre-existing conditions that increase in', 'severity or change in nature during or as a consequence of participation in the clinical study', 'will also be considered AEs.', '9.1.2. Serious Adverse Events', 'An SAE is defined as an AE that:', '-', 'Results in death.', '-', 'Is life-threatening (Note: The term \"life-threatening\\' in the definition of \\'serious\\' refers', 'to an event in which the subject was at risk of death at the time of the event; it does not', 'refer to an event that hypothetically might have caused death if it were more severe.).', '-', 'Requires in-patient hospitalization or prolongation of existing hospitalization.', '-', 'Results in persistent or significant disability/incapacity.', '-', 'Is a congenital anomaly/birth defect.', '-', 'Is medically significant (medical and scientific judgment should be exercised in deciding', 'whether other situations should be considered serious such as important medical events', 'that might not be immediately life-threatening or result in death or hospitalization but', 'might jeopardize the subject or might require intervention to prevent one of the other', 'outcomes listed in the definition above).', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}